• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Pruritus - Pipeline Review, H2 2012 Product Image

Pruritus - Pipeline Review, H2 2012

  • ID: 2298863
  • October 2012
  • 47 pages
  • Global Markets Direct

Pruritus – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Pruritus - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Pruritus, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pruritus. Pruritus - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Pruritus.
- A review of the Pruritus products under development by companies and universities/research institutes based on information derived from company and industry-specific READ MORE >

2
List of Tables 4
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Pruritus Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Pruritus 8
Pruritus Therapeutics under Development by Companies 10
Pruritus Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Pre-Clinical Stage Products 15
Comparative Analysis 15
Pruritus Therapeutics – Products under Development by Companies 16
Pruritus Therapeutics – Products under Investigation by Universities/Institutes 17
Companies Involved in Pruritus Therapeutics Development 18
GlaxoSmithKline plc 18
Nippon Shinyaku Co., Ltd. 19
Array BioPharma Inc. 20
KYORIN Pharmaceutical Co., Ltd. 21
Maruho Co.,Ltd. 22
Pruritus – Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
SB-705498 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
nalfurafine hydrochloride - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
NST-141 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
colesevelam hydrochloride - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
naloxone hydrochloride - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
M5-16102 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
KRP-110 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
T-111 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
sucralfate - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
ARRY-005 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Pruritus Therapeutics – Drug Profile Updates 41
Pruritus Therapeutics – Discontinued Products 42
Pruritus Therapeutics - Dormant Products 43
Pruritus – Product Development Milestones 44
Featured News & Press Releases 44
Dec 22, 2011: Toray, Japan Tobacco And Torii Terminate Joint Development Of Nalfurafine Hydrochloride For Pruritus Associated With Liver Disease In Japan 44
Sep 29, 2011: Trevi Therapeutics Initiates Phase II Study of T111 For Treatment Of Chronic Uremic Pruritus 44
Sep 27, 2011: Trevi Therapeutics Announces Incorporation And Phase II Development Of T111 44
Jul 21, 2011: Merz Aesthetics Announces FDA Approval Of XEOMIN For Temporary Improvement In Appearance Of Moderate To Severe Glabellar Lines In Adult Patients 45
Sep 22, 2005: Aqua Pharmaceuticals Licenses Cordran and Monodox for the United States 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer 47

List of Tables
Number of Products Under Development for Pruritus, H2 2012 8
Products under Development for Pruritus – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Early Clinical Stage Development, H2 2012 14
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 17
GlaxoSmithKline plc, H2 2012 18
Nippon Shinyaku Co., Ltd., H2 2012 19
Array BioPharma Inc., H2 2012 20
KYORIN Pharmaceutical Co., Ltd., H2 2012 21
Maruho Co.,Ltd., H2 2012 22
Assessment by Monotherapy Products, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 27
Pruritus Therapeutics – Drug Profile Updates 41
Pruritus Therapeutics – Discontinued Products 42
Pruritus Therapeutics – Dormant Products 43

List of Figures
Number of Products under Development for Pruritus, H2 2012 8
Products under Development for Pruritus – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Early Clinical Stage Products, H2 2012 14
Pre-Clinical Stage Products, H2 2012 15
Assessment by Monotherapy Products, H2 2012 23
Assessment by Route of Administration, H2 2012 24
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Molecule Type, H2 2012 26
Assessment by Stage and Molecule Type, H2 2012 27

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos